One prospective study demonstrated interactions between HLA expression and other biomarkers such as tumor mutational load, PD-L1 expression, and infiltrating CD8 T cells as predictors of response to single-agent nivolumab in NSCLC, but no difference when stratified by HLA loss alone [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.